Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours

European Journal of Cancer

Volumn 40, Issue 9, 2004, Pages 1373-1382

  Mennerich, D ^a   Vogel, A ^b   Klaman, I ^b   Dahl, E ^b   Lichtner, R B ^b   Rosenthal, A ^b   Pohlenz, H D ^a   Thierauch, K H ^a   Sommer, A ^a  

^a BAYER PHARMA AG   (Germany)

^b MetaGen Pharmaceuticals GmbH   (Germany)

Author keywords

Expression profiling; Microdissection; Syndecan 1; Tumour stroma

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; SYNDECAN 1;

ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CELL DIFFERENTIATION; COLON CARCINOMA; CONNECTIVE TISSUE; CONTROLLED STUDY; DNA MICROARRAY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG CARCINOMA; MALE; METASTASIS; MICRODISSECTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SOLID TUMOR; SPINDLE CELL; STROMA CELL; UPREGULATION;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DNA FINGERPRINTING; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASMS; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTEOGLYCANS; RNA, MESSENGER; STROMAL CELLS; SYNDECAN-1; SYNDECANS;

EID: 2942575983     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.01.038     Document Type: Article

References (32)

1. Rapraeger A.C., Ott V.L. Molecular interactions of the syndecan core proteins. Curr. Opin. Cell. Biol. 10(5):1998;620-628
2. Bernfield M., Gotte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J., et al. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68:1999;729-777
3. Rapraeger A.C. Syndecan-regulated receptor signaling. J. Cell Biol. 149(5):2000;995-998
4. Zimmermann P., David G. The syndecans, tuners of transmembrane signaling. FASEB J. 13(Suppl):1999;S91-S100
5. Carey D.J. Syndecans: multifunctional cell-surface co-receptors. Biochem. J. 327(Pt 1):1997;1-16
6. Kim C.W., Goldberger O.A., Gallo R.L., Bernfield M. Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol. Biol. Cell. 5(7):1994;797-805
7. Volk R., Schwartz J.J., Li J., Rosenberg R.D., Simons M. The role of syndecan cytoplasmic domain in basic fibroblast growth factor-dependent signal transduction. J. Biol. Chem. 274(34):1999;24417-24424
8. Fitzgerald M.L., Wang Z., Park P.W., Murphy G., Bernfield M. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J. Cell Biol. 148(4):2000;811-824
9. Seidel C., Sundan A., Hjorth M., Turesson I., Dahl I.M., Abildgaard N., et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood. 95(2):2000;388-392
10. Buczek-Thomas J.A., Nugent M.A. Elastase-mediated release of heparan sulfate proteoglycans from pulmonary fibroblast cultures. A mechanism for basic fibroblast growth factor (bFGF) release and attenuation of bFGF binding following elastase-induced injury. J. Biol. Chem. 274(35):1999;25167-25172
11. Subramanian S.V., Fitzgerald M.L., Bernfield M. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J. Biol. Chem. 272(23):1997;14713-14720
12. Inki P., Joensuu H., Grenman R., Klemi P., Jalkanen M. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br. J. Cancer. 70(2):1994;319-323
13. Anttonen A., Kajanti M., Heikkila P., Jalkanen M., Joensuu H. Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br. J. Cancer. 79(3-4):1999;558-564
14. Pulkkinen J.O., Penttinen M., Jalkanen M., Klemi P., Grenman R. Syndecan-1: a new prognostic marker in laryngeal cancer. Acta Otolaryngol. 117(2):1997;312-315
15. Kumar-Singh S., Jacobs W., Dhaene K., Weyn B., Bogers J., Weyler J., et al. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J. Pathol. 186(3):1998;300-305
16. Nackaerts K., Verbeken E., Deneffe G., Vanderschueren B., Demedts M., David G. Heparan sulfate proteoglycan expression in human lung-cancer cells. Int. J. Cancer. 74(3):1997;335-345
17. Joensuu H., Anttonen A., Eriksson M., Makitaro R., Alfthan H., Kinnula V., et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res. 62(18):2002;5210-5217
18. Matsumoto A., Ono M., Fujimoto Y., Gallo R.L., Bernfield M., Kohgo Y. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int. J. Cancer. 74(5):1997;482-491
19. Wiksten J.P., Lundin J., Nordling S., Kokkola A., Haglund C. A prognostic value of syndecan-1 in gastric cancer. Anticancer Res. 20(6D):2000;4905-4907
20. Wiksten J.P., Lundin J., Nordling S., Lundin M., Kokkola A., von Boguslawski K., et al. Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int. J. Cancer. 95(1):2001;1-6
21. Stanley M.J., Stanley M.W., Sanderson R.D., Zera R. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am. J. Clin. Pathol. 112(3):1999;377-383
22. Conejo J.R., Kleeff J., Koliopanos A., Matsuda K., Zhu Z.W., Goecke H., et al. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int. J. Cancer. 88(1):2000;12-20
23. Luo L., Salunga R.C., Guo H., Bittner A., Joy K.C., Galindo J.E., et al. Gene expression profiles of laser-captured adjacent neuronal subtypes. Nat. Med. 5(1):1999;117-122
24. Kristiansen G., Pilarsky C., Wissmann C., Stephan C., Weissbach L., Loy V., et al. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate. 54(1):2003;34-43
25. Zhumabayeva B., Diatchenko L., Chenchik A., Siebert P.D. Use of SMART-generated cDNA for gene expression studies in multiple human tumors. Biotechniques. 30(1):2001;158-163
26. Wijdenes J., Dore J.M., Clement C., Vermot-Desroches C. Cd138. J. Biol. Regul. Homeost Agents. 16(2):2002;152-155
27. Schmitt-Graff A., Gabbiani G. Phenotypic features of stromal cells in normal, premalignant and malignant conditions. Eur. J. Cancer. 11(20):1992;1916-1920
28. Matsuda K., Maruyama H., Guo F., Kleeff J., Itakura J., Matsumoto Y., et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 61(14):2001;5562-5569
29. Petersen O.W., Nielsen H.L., Gudjonsson T., Villadsen R., Rank F., Niebuhr E., et al. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am. J. Pathol. 162(2):2003;391-402
30. Kato M., Saunders S., Nguyen H., Bernfield M. Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol. Biol. Cell. 6(5):1995;559-576
31. Jiang R., Kato M., Bernfield M., Grabel L.B. Expression of syndecan-1 changes during the differentiation of visceral and parietal endoderm from murine F9 teratocarcinoma cells. Differentiation. 59(4):1995;225-233
32. Seidel C., Borset M., Hjertner O., Cao D., Abildgaard N., Hjorth-Hansen H., et al. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood. 96(9):2000;3139-3146